Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial

Safety and Immunogenicity of an Inactivated Quadrivalent Influenza Vaccine in Children 6 Months through 8 Years of Age

(2014) David P. Greenberg et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The Potential Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in Elderly People and Clinical Risk Groups in the UK: A Lifetime Multi-Cohort Model

(2014) Laure-Anne Van Bellinghen et al.   PLoS One

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial

(2014) Juan Carlos Tinoco et al.   VACCINE

Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States

(2014) Karen M Clements et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial

(2014) Joanne M. Langley et al.   Journal of the Pediatric Infectious Diseases Society

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

(2013) Dorothee Kieninger et al.   BMC INFECTIOUS DISEASES

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children

(2013) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3–17 Years

(2013) Joseph B. Domachowske et al.   JOURNAL OF INFECTIOUS DISEASES

Vaccine for Prevention of Mild and Moderate-to-Severe Influenza in Children

(2013) Varsha K. Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults

(2013) Stéphanie Pépin et al.   VACCINE

A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age

(2013) Noris Pavia-Ruz et al.   Human Vaccines & Immunotherapeutics

Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine

(2012) Carrie Reed et al.   VACCINE

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults

(2012) David P. Greenberg et al.   VACCINE

Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6–35 Months: A Randomized, Controlled Trial

(2012) Joanne M. Langley et al.   Journal of the Pediatric Infectious Diseases Society

Randomized Controlled Trial of Dose Response to Influenza Vaccine in Children Aged 6 to 23 Months

(2011) D. M. Skowronski et al.   PEDIATRICS

Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: Do children of all ages respond equally?

(2010) Emmanuel B. Walter et al.   VACCINE

Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity

(2009) Robert B. Belshe et al.   VACCINE

Effectiveness of Inactivated Influenza Vaccines Varied Substantially with Antigenic Match from the 2004–2005 Season to the 2006–2007 Season

(2008) Edward A. Belongia et al.   JOURNAL OF INFECTIOUS DISEASES